CIK 0001657312
VRNA Verona Pharma plc
Insider trading from SEC Form 4. Last filing Oct 8, 2025.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
14
with a Form 4 at this company
Signals
Open-market buys and sells at Verona Pharma plc, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 15Weak | Christina Ackermann director sell | $24k 1,808 shares | -3% | - | |
| 36Weak | Michael Austwick director sell | $148k 11,288 shares | -47% | - | |
| 15Weak | James Aloysius Brady director sell | $11k 824 shares | -3% | - | |
| 31Weak | Kenneth Cunningham director sell | $142k 10,808 shares | -12% | - | |
| 30Weak | Lisa Deschamps director sell | $124k 9,464 shares | -10% | - | |
| 20Weak | David R Ebsworth director sell | $25k 1,904 shares | -0% | - | |
| 26Weak | Martin Edwards director sell | $142k 10,808 shares | -6% | - | |
| 26Weak | Andrew Fisher General Counsel sell | $126k 9,584 shares | -2% | - | |
| 27Weak | Mark W Hahn Chief Financial Officer sell | $2.7M 208,912 shares | -2% | - | |
| 17Weak | Kathleen A. Rickard Chief Medical Officer sell | $767k 58,336 shares | -2% | - | |
| 21Weak | Mahendra Shah director sell | $47k 3,608 shares | -4% | - | |
| 22Weak | Vikas Sinha director sell | $57k 4,328 shares | -4% | - | |
| 30Weak | David Zaccardelli President and CEO sell | $2.7M 208,912 shares | -2% | - | |
| 24Weak | Andrew Fisher General Counsel sell | $922k 80,000 shares | -18% | - | |
| 42Moderate | Mark W Hahn Chief Financial Officer sell | $4.6M 400,000 shares | -3% | - | |
| 45Moderate | David Zaccardelli President and CEO sell | $4.6M 400,000 shares | -3% | - | |
| 42Moderate | Mark W Hahn Chief Financial Officer sell | $3.7M 400,000 shares | -3% | - | |
| 45Moderate | David Zaccardelli President and CEO sell | $3.7M 400,000 shares | -3% | - | |
| 40Moderate | Vikas Sinha director sell | $1.5M 160,000 shares | -68% | - | |
| 40Moderate | Vikas Sinha director sell | $1.4M 160,000 shares | -82% | - | |
| 20Weak | Christina Ackermann director sell | $338k 40,000 shares | -49% | - | |
| 21Weak | Andrew Fisher General Counsel sell | $686k 80,000 shares | -18% | - | |
| 35Weak | Kathleen A. Rickard Chief Medical Officer sell | $1.0M 114,984 shares | -4% | - | |
| 27Weak | Mark W Hahn Chief Financial Officer sell | $5.3M 587,008 shares | -4% | - | |
| 12Weak | Kathleen A. Rickard Chief Medical Officer sell | $440k 49,200 shares | -2% | - | |
| 30Weak | David Zaccardelli President and CEO sell | $5.3M 587,008 shares | -4% | - | |
| 28Weak | Andrew Fisher General Counsel sell | $234k 26,072 shares | -7% | - | |
| 24Weak | Mark W Hahn Chief Financial Officer sell | $811k 90,360 shares | -1% | - | |
| 9Weak | Kathleen A. Rickard Chief Medical Officer sell | $309k 34,384 shares | -1% | - | |
| 12Weak | Vikas Sinha director sell | $178k 20,000 shares | -22% | - | |
| 27Weak | David Zaccardelli President and CEO sell | $811k 90,360 shares | -1% | - | |
| 42Moderate | Mark W Hahn Chief Financial Officer sell | $4.4M 881,960 shares | -6% | - | |
| 45Moderate | David Zaccardelli President and CEO sell | $4.4M 870,672 shares | -6% | - | |
| 36Weak | Mark W Hahn Chief Financial Officer sell | $567k 113,240 shares | -1% | - | |
| 40Moderate | David Zaccardelli President and CEO sell | $627k 125,328 shares | -1% | - | |
| 17Weak | Mark W Hahn Chief Financial Officer sell | $12k 2,400 shares | -0% | - | |
| 35Weak | Kathleen A. Rickard Chief Medical Officer sell | $1.2M 240,000 shares | -8% | - | |
| 20Weak | David Zaccardelli President and CEO sell | $8,000 1,600 shares | -0% | - | |
| 37Weak | David R Ebsworth director buy | $89k 20,000 shares | +2% | - | |
| 17Weak | Mark W Hahn Chief Financial Officer sell | $12k 2,400 shares | -0% | - | |
| 20Weak | David Zaccardelli President and CEO sell | $12k 2,400 shares | -0% | - | |
| 43Moderate | Christina Ackermann director buy | $198k 41,880 shares | - | - | |
| 35Weak | David R Ebsworth director buy | $189k 39,360 shares | +4% | - | |
| 29Weak | Mark W Hahn Chief Financial Officer sell | $568k 129,672 shares | -1% | - | |
| 33Weak | David Zaccardelli President and CEO sell | $619k 141,032 shares | -1% | - | |
| 30Weak | Mark W Hahn Chief Financial Officer sell | $633k 144,560 shares | -1% | - | |
| 33Weak | David Zaccardelli President and CEO sell | $634k 144,816 shares | -1% | - | |
| 35Weak | Mark W Hahn Chief Financial Officer sell | $2.3M 525,768 shares | -4% | - | |
| 38Weak | David Zaccardelli President and CEO sell | $2.3M 514,152 shares | -3% | - |
Transactions
The last 100 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Oct 7, 2025 | David R Ebsworth director | DDisposition to issuer Ordinary Shares | -880,499 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Vikas Sinha director | DDisposition to issuer Ordinary Shares | -94,112 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mark W Hahn Chief Financial Officer | DDisposition to issuer Ordinary Shares | -11,264,968 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Lisa Deschamps director | DDisposition to issuer Ordinary Shares | -84,856 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | James Aloysius Brady director | DDisposition to issuer Ordinary Shares | -23,176 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Christina Ackermann director | DDisposition to issuer Ordinary Shares | -64,072 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Andrew Fisher General Counsel | DDisposition to issuer Ordinary Shares | -417,903 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mahendra Shah director | DDisposition to issuer Ordinary Shares | -93,472 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Martin Edwards director | DDisposition to issuer Ordinary Shares | -157,992 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kathleen A. Rickard Chief Medical Officer | DDisposition to issuer Ordinary Shares | -2,432,868 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kenneth Cunningham director | DDisposition to issuer Ordinary Shares | -79,776 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | David Zaccardelli President and CEO | DDisposition to issuer Ordinary Shares | -12,176,144 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Anders Ullman director | DDisposition to issuer Ordinary Shares | -358,856 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Michael Austwick director | DDisposition to issuer Ordinary Shares | -12,712 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Christina Ackermann director | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | David R Ebsworth director | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | Vikas Sinha director | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | Michael Austwick director | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | Kathleen A. Rickard Chief Medical Officer | MOption exercise Ordinary Shares | +1,131,984 | - | - | 1,131,984 | Oct 8, 2025 |
| Oct 7, 2025 | Anders Ullman director | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | Mahendra Shah director | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | David Zaccardelli President and CEO | MOption exercise Ordinary Shares | +3,285,280 | - | - | 3,285,280 | Oct 8, 2025 |
| Oct 7, 2025 | Martin Edwards director | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | Kenneth Cunningham director | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | Andrew Fisher General Counsel | MOption exercise Ordinary Shares | +931,984 | - | - | 931,984 | Oct 8, 2025 |
| Oct 7, 2025 | James Aloysius Brady director | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | Mark W Hahn Chief Financial Officer | MOption exercise Ordinary Shares | +3,285,280 | - | - | 3,285,280 | Oct 8, 2025 |
| Oct 7, 2025 | Lisa Deschamps director | MOption exercise Ordinary Shares | +72,000 | - | - | 72,000 | Oct 8, 2025 |
| Oct 7, 2025 | Mahendra Shah director | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kenneth Cunningham director | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Michael Austwick director | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | James Aloysius Brady director | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | David R Ebsworth director | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Martin Edwards director | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mark W Hahn Chief Financial Officer | DDisposition to issuer Ordinary Shares | -3,285,280 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kathleen A. Rickard Chief Medical Officer | DDisposition to issuer Ordinary Shares | -1,131,984 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Vikas Sinha director | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Andrew Fisher General Counsel | DDisposition to issuer Ordinary Shares | -931,984 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Anders Ullman director | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | David Zaccardelli President and CEO | DDisposition to issuer Ordinary Shares | -3,285,280 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Lisa Deschamps director | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Christina Ackermann director | DDisposition to issuer Ordinary Shares | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Martin Edwards director | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kathleen A. Rickard Chief Medical Officer | MOption exercise Restricted Share Unitderivative | -146,168 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Christina Ackermann director | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mahendra Shah director | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Michael Austwick director | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Vikas Sinha director | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kenneth Cunningham director | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | David R Ebsworth director | DDisposition to issuer Ordinary Sharesindirect: By Ebsworth GmbH | -617,600 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Anders Ullman director | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Andrew Fisher General Counsel | MOption exercise Restricted Share Unitderivative | -146,168 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | David Zaccardelli President and CEO | MOption exercise Restricted Share Unitderivative | -800,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mark W Hahn Chief Financial Officer | MOption exercise Restricted Share Unitderivative | -800,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Lisa Deschamps director | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | James Aloysius Brady director | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | James Aloysius Brady director | DDisposition to issuer Share Options (Right to Buy)derivative | -288,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kathleen A. Rickard Chief Medical Officer | MOption exercise Restricted Share Unitderivative | -167,056 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mahendra Shah director | DDisposition to issuer Share Options (Right to Buy)derivative | -200,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | David R Ebsworth director | MOption exercise Restricted Share Unitderivative | -72,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Christina Ackermann director | DDisposition to issuer Share Options (Right to Buy)derivative | -200,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Vikas Sinha director | DDisposition to issuer Share Options (Right to Buy)derivative | -384 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Martin Edwards director | DDisposition to issuer Share Options (Right to Buy)derivative | -200,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Michael Austwick director | DDisposition to issuer Share Options (Right to Buy)derivative | -144,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Anders Ullman director | DDisposition to issuer Share Options (Right to Buy)derivative | -200,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kenneth Cunningham director | DDisposition to issuer Share Options (Right to Buy)derivative | -200,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Andrew Fisher General Counsel | MOption exercise Restricted Share Unitderivative | -167,056 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mark W Hahn Chief Financial Officer | MOption exercise Restricted Share Unitderivative | -389,792 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | David Zaccardelli President and CEO | MOption exercise Restricted Share Unitderivative | -389,792 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Lisa Deschamps director | DDisposition to issuer Share Options (Right to Buy)derivative | -200,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Lisa Deschamps director | DDisposition to issuer Share Options (Right to Buy)derivative | -96,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kathleen A. Rickard Chief Medical Officer | MOption exercise Restricted Share Unitderivative | -200,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | James Aloysius Brady director | DDisposition to issuer Share Options (Right to Buy)derivative | -96,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mahendra Shah director | DDisposition to issuer Share Options (Right to Buy)derivative | -96,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Vikas Sinha director | DDisposition to issuer Share Options (Right to Buy)derivative | -96,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Martin Edwards director | DDisposition to issuer Share Options (Right to Buy)derivative | -96,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Anders Ullman director | DDisposition to issuer Share Options (Right to Buy)derivative | -96,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kenneth Cunningham director | DDisposition to issuer Share Options (Right to Buy)derivative | -96,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | David Zaccardelli President and CEO | MOption exercise Restricted Share Unitderivative | -445,536 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Christina Ackermann director | DDisposition to issuer Share Options (Right to Buy)derivative | -144,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Andrew Fisher General Counsel | AGrant or award Restricted Share Unitderivative | +618,760 | - | - | 618,760 | Oct 8, 2025 |
| Oct 7, 2025 | Mark W Hahn Chief Financial Officer | MOption exercise Restricted Share Unitderivative | -445,536 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Lisa Deschamps director | DDisposition to issuer Share Options (Right to Buy)derivative | -240,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kathleen A. Rickard Chief Medical Officer | AGrant or award Restricted Share Unitderivative | +618,760 | - | - | 618,760 | Oct 8, 2025 |
| Oct 7, 2025 | James Aloysius Brady director | DDisposition to issuer Share Options (Right to Buy)derivative | -240,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mahendra Shah director | DDisposition to issuer Share Options (Right to Buy)derivative | -240,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Vikas Sinha director | DDisposition to issuer Share Options (Right to Buy)derivative | -240,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Martin Edwards director | DDisposition to issuer Share Options (Right to Buy)derivative | -240,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Anders Ullman director | DDisposition to issuer Share Options (Right to Buy)derivative | -240,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | David Zaccardelli President and CEO | AGrant or award Restricted Share Unitderivative | +1,649,952 | - | - | 1,649,952 | Oct 8, 2025 |
| Oct 7, 2025 | Kenneth Cunningham director | DDisposition to issuer Share Options (Right to Buy)derivative | -240,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Andrew Fisher General Counsel | MOption exercise Restricted Share Unitderivative | -618,760 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mark W Hahn Chief Financial Officer | AGrant or award Restricted Share Unitderivative | +1,649,952 | - | - | 1,649,952 | Oct 8, 2025 |
| Oct 7, 2025 | Lisa Deschamps director | DDisposition to issuer Share Options (Right to Buy)derivative | -64,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kathleen A. Rickard Chief Medical Officer | MOption exercise Restricted Share Unitderivative | -618,760 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Mahendra Shah director | DDisposition to issuer Share Options (Right to Buy)derivative | -64,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Vikas Sinha director | DDisposition to issuer Share Options (Right to Buy)derivative | -64,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Martin Edwards director | DDisposition to issuer Share Options (Right to Buy)derivative | -64,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Anders Ullman director | DDisposition to issuer Share Options (Right to Buy)derivative | -64,000 | - | - | 0 | Oct 8, 2025 |
| Oct 7, 2025 | Kenneth Cunningham director | DDisposition to issuer Share Options (Right to Buy)derivative | -64,000 | - | - | 0 | Oct 8, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Christina Ackermanndirector
- Michael Austwickdirector
- James Aloysius Bradydirector
- Kenneth Cunninghamdirector
- Lisa Deschampsdirector
- David R Ebsworthdirector
- Martin Edwardsdirector
- Andrew FisherGeneral Counsel
- Mark W HahnChief Financial Officer
- Kathleen A. RickardChief Medical Officer
- Mahendra Shahdirector
- Vikas Sinhaofficer, director, owner, cfo
- Anders Ullmandirector
- David ZaccardelliPresident and CEO
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.